Eurobio Scientific: a look back at the successful takeover bid with an imminent reopening

On November 29, 2024, Eurobio Scientific and EB Development announced the success of the public tender offer (OPA) launched by EB Development. The AMF confirmed that 44.72% of the capital and voting rights of Eurobio Scientific had been contributed to this offer.

At the closing of the offer on November 27, 4,582,971 shares had been tendered. EB Development, in collaboration with NextStage AM, IK Partners, and Eurobio executives, thus holds 82.68% of the capital. The reopening of the offer is scheduled from December 4 to 17, 2024.

The takeover bid price is 25.30 euros per share, plus a supplement of 1.25 euros if 90% of the capital is reached. Excluding the supplement, the offer represents a premium of 39% on the last closing price before the announcement.

The board of directors recommends that shareholders tender their shares, stressing that the listing no longer promotes the company's development.